Pharmaceutical and clinical studies of celecoxib topical hydrogel for management of chemotherapy-induced hand-foot syndrome
Authors:
- 24 November 2022
- journal article
- research article
- Published by Springer Nature in Naunyn-Schmiedeberg's Archives of Pharmacology
- Vol. 396 (7) , 1571-1581
Abstract
Hand-foot syndrome (HFS) can be categorized as a frequent dose-limiting side effect following administration of chemotherapeutic agents, which needs an effective medication to avoid dose reduction or discontinuation. Oral celecoxib has been proved to be the best pharmacological intervention to ameliorate the skin lesions. However, due to reported gastrointestinal and cardiovascular toxicity following its long-term administration, celecoxib topical application would be a safe alternative for skin disorders. In this work, first, we formulated and optimized a topical hydrogel of celecoxib (1%) and then we investigated its efficacy in the management of chemotherapy-induced HFS in cancer patients. Optimized hydrogel showed acceptable results for drug content, pH, rheology, and stability. Analyzing in vitro drug release study by various mathematical models, the optimized hydrogel showed a zero-order release pattern with 93.27 ± 1.56% cumulative celecoxib release within 8 h. Ex vivo permeation studies across Wistar rat skin indicated suitable skin retention of celecoxib for topical delivery. Twenty-nine patients suffering from HFS were randomized to receive celecoxib and the placebo hydrogels 2 times a day for 3 weeks. At the baseline and at the end of the trial, HFS grades were determined. No serious adverse events occurred in patients who completely followed the instructions. No statistically significant differences between two arms were observed at the baseline (p value = 0.38). By contrast, Wilcoxon signed-rank test showed significant differences when secondary grades (p value = 0.05) and grade differences (p values < 0.001) were analyzed. Overall, the study proved that celecoxib hydrogel could be a promising intervention to manage HFS side effect. Graphical AbstractKeywords
This publication has 35 references indexed in Scilit:
- Preparation and characterization of novel carbopol based bigels for topical delivery of metronidazole for the treatment of bacterial vaginosisMaterials Science and Engineering: C, 2014
- Treatment of palmar-plantar erythrodysesthesia (PPE) with topical sildenafil: a pilot studySupportive Care in Cancer, 2014
- Prevention of palmar–plantar erythrodysesthesia with an antiperspirant in breast cancer patients treated with pegylated liposomal doxorubicin (SAKK 92/08)The Breast, 2014
- Prevention strategies for chemotherapy-induced hand–foot syndrome: a systematic review and meta-analysis of prospective randomised trialsSupportive Care in Cancer, 2014
- Adverse reactions to targeted and non-targeted chemotherapeutic drugs with emphasis on hypersensitivity responses and the invasive metastatic switchCancer and Metastasis Reviews, 2013
- In vitroandin vivoinfluence of penetration enhancers in the topical application of celecoxibDrug Development and Industrial Pharmacy, 2013
- Celecoxib can prevent capecitabine-related hand-foot syndrome in stage II and III colorectal cancer patients: result of a single-center, prospective randomized phase III trialAnnals of Oncology, 2011
- The effect of COX-2 inhibitor on capecitabine-induced hand–foot syndrome in patients with stage II/III colorectal cancer: a phase II randomized prospective studyJournal of Cancer Research and Clinical Oncology, 2010
- A Stability-Indicating HPLC Method to Determine Celecoxib in Capsule FormulationsDrug Development and Industrial Pharmacy, 2002
- Heat-separation of normal human skin for epidermal and dermal prostaglandin analysisArchives of Dermatological Research, 1982